Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Clinical Trial
. 2016 Apr;59(4):386-97.
doi: 10.1007/s11427-016-5024-7. Epub 2016 Mar 7.

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

Fengtao You  1   2   3 , Licui Jiang  2   3 , Bozhen Zhang  2   3 , Qiang Lu  4 , Qiao Zhou  4 , Xiaoyang Liao  4 , Hong Wu  4 , Kaiqi Du  5 , Youcai Zhu  5 , Huimin Meng  1 , Zhishu Gong  6 , Yunhui Zong  2   3 , Lei Huang  2   3 , Man Lu  2   3 , Jirong Tang  2   3 , Yafen Li  2   3 , Xiaochen Zhai  7 , Xiangling Wang  7 , Sisi Ye  2   3 , Dan Chen  2   3 , Lei Yuan  8 , Lin Qi  2   3 , Lin Yang  9   10   11   12
Affiliations
Clinical Trial

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

Fengtao You (VSports app下载) et al. Sci China Life Sci. 2016 Apr.

Abstract

Recent progress in chimeric antigen receptor-modified T-cell (CAR-T cell) technology in cancer therapy is extremely promising, especially in the treatment of patients with B-cell acute lymphoblastic leukemia. In contrast, due to the hostile immunosuppressive microenvironment of a solid tumor, CAR T-cell accessibility and survival continue to pose a considerable challenge, which leads to their limited therapeutic efficacy. In this study, we constructed two anti-MUC1 CAR-T cell lines VSports手机版. One set of CAR-T cells contained SM3 single chain variable fragment (scFv) sequence specifically targeting the MUC1 antigen and co-expressing interleukin (IL) 12 (named SM3-CAR). The other CAR-T cell line carried the SM3 scFv sequence modified to improve its binding to MUC1 antigen (named pSM3-CAR) but did not co-express IL-12. When those two types of CAR-T cells were injected intratumorally into two independent metastatic lesions of the same MUC1(+) seminal vesicle cancer patient as part of an interventional treatment strategy, the initial results indicated no side-effects of the MUC1 targeting CAR-T cell approach, and patient serum cytokines responses were positive. Further evaluation showed that pSM3-CAR effectively caused tumor necrosis, providing new options for improved CAR-T therapy in solid tumors. .

Keywords: CAR-T therapy; MUC1; seminal vesicle cancer; solid tumor V体育安卓版. .

PubMed Disclaimer

Publication types

MeSH terms

"VSports注册入口" LinkOut - more resources